FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379517866> ?p ?o ?g. }

• W4379517866 endingPage "474" @default.
• W4379517866 startingPage "473.2" @default.
• W4379517866 abstract "Background In spite of advancements in treatment of ankylosing spondylitis (AS), its pathogenesis remains incompletely understood. The current evidence suggests that AS is both an autoinflammatory and autoimmune disease involving innate immune cells along with autoreactive lymphocytes. B cells have received little attention regarding their role in the pathogenesis of ankylosing spondylitis (AS), although the available evidence shows presence of B cells at inflammatory sites, imbalances in B cell subsets, presence of autoantibodies (anti-CD74/CLIP), and beneficial effects of B cell depletion (anti-CD20) with rituximab [1]. In AS, the overarching picture portrays increased B cell activation, although it is unclear whether B cells directly affect pathogenesis, or are merely bystanders in the disease process. Objectives Our main objective was to study gene expression and gene signalling pathways involved in B cell activation in AS. To this end, we analysed the transcriptomic profile of isolated peripheral B cells from AS patients, healthy donors (HD) and patients with primary Sjögren syndrome (pSS), a typical B-cell-associated autoimmune disease. Methods RNA was isolated from CD19 + B cells sorted from peripheral blood mononuclear cells of 8 AS patients (mean age 48.0 ± 9.7 years, 63% male, mean ASDAS 2.5 ± 0.7), 8 sex and age-matched HDs (42.3 ± 17.8 years, 63% male) and 8 age-matched pSS patients (48.4 ± 17.8 years, 13% male). Next, characterization of differentially expressed genes was performed using transcriptomic analysis by the NanoString nCounter Autoimmune Profiling Panel, which utilizes a direct hybridization technique without PCR amplification. After normalization and z-score scaling of pathway genes, pathway scores were calculated based on the first principle component using nCounter advanced analysis software. P-values <0.05 were considered significant. Results All samples passed quality control, except for one pSS patient sample that was being flagged as an outlier by the nCounter advanced analyses software. Analysis of differential gene expression between AS patients and HDs revealed upregulation of 8 genes, including MAPK14 , KMT2A and PKM , in B cells from AS patients, and downregulation of two genes, DDIT4 and ATG5 . In AS patients, the relative expression of B cell receptor (BCR) signalling (n=60 genes) and Fc receptors and phagocytosis (n=55 genes) pathway genes were both significantly enriched compared to HDs ( Figure 1 ). Although not significant, these pathways also displayed higher pathway scores in pSS patients compared to HDs (P=0.30 and P=0.37, respectively). Other gene pathways involved in B cell activation, such as toll-like receptor signalling were not significantly enriched. Conclusion In this study, we observed several differentially expressed genes involved in signal transduction pathways in B cells from AS patients. Furthermore, we showed increased expression of gene pathways involved in B cell activation in patients with AS compared to HDs. The BCR-mediated activation in AS displays similarities to a bona fide autoimmune disease pSS. These results suggest active involvement of B cells in the disease process of AS. Reference [1]Wilbrink, R et al. (2021). B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis. International journal of molecular sciences . Figure 1. Gene pathway scores of (A) B cell receptor signalling and (B) Fc receptors and phagocytosis between AS, pSS patients and HDs. P-values <0.05 were considered significant. Acknowledgements: NIL. Disclosure of Interests Rick Wilbrink: None declared, Anneke Spoorenberg Consultant of: Abbvie, Pfizer, MSD, UCB, Lilly and Novartis, Grant/research support from: Abbvie, Pfizer, Union Chimique Belge (UCB), Novartis, Frans G.M. Kroese Speakers bureau: BMS Roche and Jannsen-Cilag, Consultant of: BMS, Grant/research support from: unrestricted grants from BMS, Gwenny M. Verstappen: None declared." @default.
• W4379517866 created "2023-06-07" @default.
• W4379517866 creator A5022628690 @default.
• W4379517866 creator A5025644959 @default.
• W4379517866 creator A5028063648 @default.
• W4379517866 creator A5052491189 @default.
• W4379517866 date "2023-05-30" @default.
• W4379517866 modified "2023-09-27" @default.
• W4379517866 title "POS0436 INCREASED EXPRESSION OF PATHWAYS INVOLVED IN B CELL ACTIVATION IN PATIENTS WITH ANKYLOSING SPONDYLITIS" @default.
• W4379517866 doi "https://doi.org/10.1136/annrheumdis-2023-eular.1192" @default.
• W4379517866 hasPublicationYear "2023" @default.
• W4379517866 type Work @default.
• W4379517866 citedByCount "0" @default.
• W4379517866 crossrefType "journal-article" @default.
• W4379517866 hasAuthorship W4379517866A5022628690 @default.
• W4379517866 hasAuthorship W4379517866A5025644959 @default.
• W4379517866 hasAuthorship W4379517866A5028063648 @default.
• W4379517866 hasAuthorship W4379517866A5052491189 @default.
• W4379517866 hasBestOaLocation W43795178661 @default.
• W4379517866 hasConcept C137061746 @default.
• W4379517866 hasConcept C159654299 @default.
• W4379517866 hasConcept C163764329 @default.
• W4379517866 hasConcept C202751555 @default.
• W4379517866 hasConcept C203014093 @default.
• W4379517866 hasConcept C2777402515 @default.
• W4379517866 hasConcept C2778453870 @default.
• W4379517866 hasConcept C2778957590 @default.
• W4379517866 hasConcept C2780130043 @default.
• W4379517866 hasConcept C2780653079 @default.
• W4379517866 hasConcept C2780942790 @default.
• W4379517866 hasConcept C54355233 @default.
• W4379517866 hasConcept C71924100 @default.
• W4379517866 hasConcept C86803240 @default.
• W4379517866 hasConcept C8891405 @default.
• W4379517866 hasConceptScore W4379517866C137061746 @default.
• W4379517866 hasConceptScore W4379517866C159654299 @default.
• W4379517866 hasConceptScore W4379517866C163764329 @default.
• W4379517866 hasConceptScore W4379517866C202751555 @default.
• W4379517866 hasConceptScore W4379517866C203014093 @default.
• W4379517866 hasConceptScore W4379517866C2777402515 @default.
• W4379517866 hasConceptScore W4379517866C2778453870 @default.
• W4379517866 hasConceptScore W4379517866C2778957590 @default.
• W4379517866 hasConceptScore W4379517866C2780130043 @default.
• W4379517866 hasConceptScore W4379517866C2780653079 @default.
• W4379517866 hasConceptScore W4379517866C2780942790 @default.
• W4379517866 hasConceptScore W4379517866C54355233 @default.
• W4379517866 hasConceptScore W4379517866C71924100 @default.
• W4379517866 hasConceptScore W4379517866C86803240 @default.
• W4379517866 hasConceptScore W4379517866C8891405 @default.
• W4379517866 hasIssue "Suppl 1" @default.
• W4379517866 hasLocation W43795178661 @default.
• W4379517866 hasOpenAccess W4379517866 @default.
• W4379517866 hasPrimaryLocation W43795178661 @default.
• W4379517866 hasRelatedWork W1583239878 @default.
• W4379517866 hasRelatedWork W1967524335 @default.
• W4379517866 hasRelatedWork W2014141678 @default.
• W4379517866 hasRelatedWork W2041746341 @default.
• W4379517866 hasRelatedWork W2060094817 @default.
• W4379517866 hasRelatedWork W2141301927 @default.
• W4379517866 hasRelatedWork W2145322348 @default.
• W4379517866 hasRelatedWork W2147153788 @default.
• W4379517866 hasRelatedWork W2267461420 @default.
• W4379517866 hasRelatedWork W2737401222 @default.
• W4379517866 hasVolume "82" @default.
• W4379517866 isParatext "false" @default.
• W4379517866 isRetracted "false" @default.
• W4379517866 workType "article" @default.